Sector Updates

Q1FY26 Earnings Preview - Pharma & Healthcare

Q1FY26 Earnings Preview - Power & Ancillaries

Bharti Airtel: For Q1FY26, we expect ARPU to come in at Rs 248 (up 1.2% QoQ) along with net subscriber addition of ~3mn. Airtel Africa business is expected to grow at 6% QoQ, and we have factored in a 4% QoQ growth rate for the enterprise...

started to taper off (highlighted in Q4FY25), and we expect the trend to continue in Q1FY26. Our outlook remains positive backed by improving margin better as they have multiple levers to deliver growth. BAF has reported steady AUM growth of 25% YoY- stable NIM and improving credit cost outlook will be...

Good quarter owing to healthy equity growth Equity QAAuM for the industry is likely to see healthy growth of 7-8% QoQ/2122% YoY in Q1FY26 due to higher MTM gains as equity market bounced back in May'25 & Jun'25. Over Mar'25 to May'25 closing eq+bal AuM for the industry grew by 8.3% (6.9% attributable to MTM) while overall AuM grew by 9.8% to Rs72.2trn. Equity/debt mix in May'25 industry MAAuM was 54.3%/16%. Equity flows saw a blip in Apr'25/May'25 (may uptick in Jun'25) due to market volatility; excl. NFOs net equity flows were Rs474bn (Rs964bn in Q4FY25). We expect AMCs in our coverage to see equity QAAuM growth of 7.7% QoQ...

LPC, DIVI to deliver healthy EBITDA growth: Amongst PL universe, we expect LPC and DIVI to report higher EBIDTA growth of 43.2% and 21.6% YoY, respectively. On the other hand, CIPLA, DRRD and ZYDUSLIF are projected to report YoY decline in EBITDA given the higher base in the US. SUNP is likely to deliver moderate revenue growth YoY led by the ramp-up in the specialty and domestic portfolios; however, higher opex will restrict EBIDTA growth....

in H1FY26. Although domestic demand remains strong aided by GoI spending, Q1FY26 volume growth seems to have affected by early monsoon, heatwaves expected to benefit from a USD10-15/t decline in coking coal costs, which have fallen to USD184/t levels. As a result, EBITDA/t for our coverage companies is expected to improve on an average ~Rs2,400/t QoQ. However, with weakened steel prices on monsoon led weakness, FY26 EBIDTA growth would depend upon demand recovery in H2FY26. Uncertainties amid ongoing tariff wars and geopolitical tensions have kept...

As per Pharma rack data, during Apr’25, the Indian pharmaceutical market (IPM) grew by 7.8% YoY, led by improved price realization (+5.1% YoY), modest new launches (+2.3% YoY), and muted volume growth (+0.4% YoY).

Q1FY26 Earnings Preview - Banks, Financial Services & Insurance (BFSI)